プロフィール詳細

プロジェクトを作成

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Dr. Shilpa P.に依頼

Canada

PhD level biologist with 8+ years of experience in cancer research (epigenetics, metabolism and therapy)

プロフィール概要

I am a passionate Research Scientist specializing in Cell & Molecular Biology, immunology, epigenetics, and translational oncology. I excel at independently managing multiple projects while fostering collaboration. I am committed to advancing translational cancer research and communicating complex science in simpler contexts. I've had the privilege of living and working across three continents and I'm always on the lookout for new opportunities. I've worked with diverse biological systems including cell lines, organoids, patient-derived xenografts, mouse models, and clinical samples. Beyond my work, I spend my days engrossed in books, engaging in creative and scientific writing, and tuning in to insightful podcasts.

専門分野

• ★ Preclinical Research
• ★ Preclinical Pharmacology
• ★ Cancer Research
• ☆ Drug Development
• ☆ Drug-Drug Interactions
• ☆ Medical Genetics
• ☆ Immunogenetics
• ☆ Human Biology
• ☆ Oncology
• ☆ Chemotherapy
• ☆ Precision Medicine
• ☆ Gastroenterology & Hepatology
• ☆ Pancreatic Cancer
• ☆ Hematology
• ☆ Leukemia & Lymphoma
• ☆ Molecular Pathology
• ☆ Immunotherapy
• ☆ Gene Therapy
• ☆ Cancer Biology
• ☆ Carcinogenesis

サービス

• Writing
• Research

Writing Technical Writing, Audio Transcription, General Proofreading & Editing

Research Scientific and Technical Research, Systematic Literature Review

職務経験

Postdoctoral Researcher

University of British Columbia

1月 2021 - 現在

Postdoctoral Researcher

University Medical Center Goettingen

7月 2020 - 12月 2020

Research Assistant

JNCASR, India

9月 2014 - 9月 2016

学歴

Ph.D

University Medical Center Goettingen

5月 2016 - 6月 2020

Masters of Science

Manipal university

7月 2012 - 7月 2014

Bachelors of Science

Manipal university

6月 2009 - 7月 2012

認定資格

• 認定資格の詳細は未入力です。

出版物

PREPRINT

Shilpa Patil, Kiyoshi Saeki, Yanping Sun, Gloria H. Su, Janel L. Kopp(2023). <i>Acvr1b</i>loss promotes formation of precancerous lesions from acinar and ductal cells of origin . Cold Spring Harbor Laboratory

Shilpa Patil, Anni Zhang, Yi Han Xia, Jeffrey S.H. Lin, Ken H. Chu, Wei Chuan K. Wang, Titine J.J. Ruiter, Jenny C.C. Yang, Nan Chen, Justin Chhuor, et al.(2022). Hyperinsulinemia acts via acinar insulin receptors to initiate pancreatic cancer by increasing digestive enzyme production and inflammation . Cold Spring Harbor Laboratory

JOURNAL ARTICLE

Zhang Z, Wang X, Hamdan FH, Likhobabina A, Patil S, Aperdannier L, Sen M, Traub J, Neesse A, Fischer A, et al. (2023). NFATc1 Is a Central Mediator of EGFR-Induced ARID1A Chromatin Dissociation During Acinar Cell Reprogramming . Cellular and molecular gastroenterology and hepatology.

Shilpa Patil, Lennart Versemann, Benjamin Steuber, Zhe Zhang, Waltraut Kopp, Hannah Elisa Krawczyk, Silke Kaulfu&#223;, Bernd Wollnik, Philipp Str&#246;bel, Albrecht Neesse, et al. (2022). TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer . Cancers.

Shilpa Patil, Yan Dou, Janel L. Kopp(2022). Cell Type of Pancreatic Ductal Adenocarcinoma Origin: Implications for Prognosis and Clinical Outcomes . Visceral Medicine. 38. (1). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 4--10. S. Karger {AG}

Shilpa Patil, Teresa Forster, Kristina Reutlinger, Waltraut Kopp, Lennart Versemann, Jessica Spitalieri, Jochen Gaedcke, Philipp Str&#246;bel, Shiv K. Singh, Volker Ellenrieder, et al. (2021). Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer . Cells.

Katharina M. Ewers, SHILPA PATIL, Waltraut Kopp, J&#252;rgen Thomale, Tabea Quilitz, Anna Magerhans, Xin Wang, Elisabeth Hessmann, Matthias Dobbelstein (2021). HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells . Cancers.

Shilpa Patil, Benjamin Steuber, Waltraut Kopp, Vijayalakshmi Kari, Laura Urbach, Xin Wang, Stefan K&#252;ffer, Hanibal Bohnenberger, Dimitra Spyropoulou, Zhe Zhang, et al.(2020). EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6 . Cancer Research. 80. (21). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 4620--4632. American Association for Cancer Research ({AACR})

Goetze RG, Buchholz SM, Ou N, Qinrong Zhang, Patil S, Schirmer M, Shiv K Singh, Ellenrieder V, Hessmann E, Lu QB, et al. (2019). Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer . Cells.

Patzak MS, Kari V, Patil S, Feda H Hamdan, Goetze RG, Marius Adler, Gaedcke J, Kitz J, Jodrell DI, Richards FM, et al. (2019). Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites . EBioMedicine.

Kaypee S, Sahadevan SA, Patil S, Ghosh P, Roy NS, Roy S, Tapas Kundu (2018). Mutant and Wild-Type Tumor Suppressor p53 Induces p300 Autoacetylation . iScience.

Kaypee S, Sahadevan SA, Sudarshan D, Halder Sinha S, Patil S, Parijat Senapati, Kodaganur GS, Mohiyuddin A, Dasgupta D, Tapas Kundu (2018). Oligomers of human histone chaperone NPM1 alter p300/KAT3B folding to induce autoacetylation . Biochimica et biophysica acta. General subjects.

Goetze RG, Buchholz SM, Patil S, Petzold G, Ellenrieder V, Hessmann E, Neesse A (2018). Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models . Journal of visualized experiments : JoVE.